Please assess the completion status of the following clinical trial:

Trial Title: Bioequivalence of NovoSeven® and a NovoSeven® Formulation Stable at Room Temperature in Healthy Male Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Caucasian~* Body Mass Index (BMI) between 18 and 27 kg/m\^2, both inclusive~* Good health as indicated by medical history, physical examination including vital signs and ECG, and clinical laboratory test results~* Smoke less than 10 cigarettes (or equivalent) per day~* Capable of giving written Informed Consent (IC)~Exclusion Criteria:~* Evidence of clinically relevant pathology or potential thromboembolic risk based on medical and/or family history as judged by the Investigator~* Known history of atherosclerosis, arteriosclerosis, thromboembolic events or known high levels of Troponin I~* Known or suspected allergy to activated recombinant human factor VII or related products or any of the components of the formulation~* Overt bleeding, including from gastrointestinal tract~* Hepatitis (B or C) infection~* HIV (human immunodeficiency virus) infection

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- CP-rFVIIa (Type: ACTIVE_COMPARATOR): None
- VII25 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).